<DOC>
	<DOCNO>NCT02525653</DOCNO>
	<brief_summary>The purpose study test safety effectiveness albumin-bound paclitaxel plus gemcitabine patient advance squamous cell lung cancer . The investigator would like determine percentage patient squamous cell lung cancer experience shrinkage tumor follow treatment regimen . This combination drug standard therapy patient squamous cell lung cancer . However , drug , give alone chemotherapy , FDA-approved treatment disease .</brief_summary>
	<brief_title>Albumin-Bound Paclitaxel Gemcitabine Patients With Untreated Stage IV Recurrent Squamous Cell Lung Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm squamous cell lung cancer Newly diagnose untreated Stage IV and/or recurrent adjuvant therapy metastatic disease Patients previously treat immune checkpoint inhibitor therapy eligible Measurable disease per RECIST 1.1 Greater 6 month since receive neoadjuvant adjuvant chemotherapy . Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Women childbearing potential sexually active men enrol study must agree practice effective contraception method treatment three month complete treatment Negative serum urine βhCG pregnancy test screening patient childbearing potential &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE ) Marrow organ function follow : ANC ≥ 1500 cells/mm3 Platelets &gt; 100,000 cells/mm3 Hemoglobin &gt; 9g/dL Creatinine clearance ≥ 40mL/min Bilirubin ≤ 1.5 mg/dL AST/ALT≤2.5 x upper limit normal range ( ULN ) , alkaline phosphatase ≤ 2.5 X upper limit normal , unless bone metastasis present absence liver metastasis Prior treatment albuminbound paclitaxel gemcitabine Prior systemic anticancer therapy advance squamous cell lung cancer Untreated brain metastasis . Patients treat brain metastasis steroid eligible Peripheral neuropathy great grade 1 Malignancies within past 5 year nonmelanoma skin cancer insitu cervical cancer status post treatment Patients serious medical illness include , ongoing active infection , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Class III IV congestive heart failure New York Heart Association</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Albumin-Bound</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>15-054</keyword>
</DOC>